Until now, clinical trials testing the potential use of ATX and LPA1 axis inhibitors in humans have been conducted predominantly on idiopathic pulmonary fibrosis and systemic sclerosis (NCT03798366, NCT01766817, NCT04308681). This evidence concerns the gene LPAR1 and pulmonary fibrosis.